Ira Mellman

Kaiser Permanente — United States

Immunology and Microbiology · Life Sciences

127h-index84.2kcitations457works9.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(115), Cancer Immunotherapy and Biomarkers(95), Cellular transport and secretion(95), Immune Cell Function and Interaction(81), T-cell and B-cell Immunology(68)

Publications456 total

Recurrent RNA-lipoplex vaccination is required to sustain functional tumor-infiltrating neoantigen-specific CD8 T cells and therapeutic efficacy
2025Open Access
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Annals of Oncology·2025· 2 cited
Cross-competition shapes CD8+ T cell hierarchies and differentiation after RNA vaccination
2025· 1 citedOpen Access
Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
A single MHCII neoepitope mRNA vaccine elicits CD4 T- and B- cell responses promoting endogenous CD8 anti-tumor immunity
2025· 1 citedOpen Access
Intratumoral cDC1-T Cell Clusters Serve as Sites of Local Costimulation to Enhance CTL-Mediated Tumor Rejection
2025· 1 citedOpen Access
Abstract LB036: TIGIT blockade promotes intratumoral Treg cells with less suppressive and more effector-like phenotype to support antitumor responses
Cancer Research·2025
Table S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
Figure S3 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
Figure S2 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
Figure S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
Figure S4 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
Data from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2025Open Access
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Nature·2025· 167 citedOpen Access
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Cancer Immunology Research·2025· 2 citedOpen Access
Publisher Correction: TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation
Nature Cancer·2025· 2 citedOpen Access
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Medicine·2025· 73 citedOpen Access
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation
Nature Cancer·2024· 29 citedOpen Access
282 Improving solid tumor CAR-T therapies by modulating T cell transcriptional states using combinatorial <i>in vitro</i> CRISPR screening followed by <i>in vivo</i> validation
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract A043: Costimulation by type 1 dendritic cells facilitates the differentiation of non-exhausted anti-tumor T cells
Cancer Immunology Research·2024
page 1 of 23Next →

Frequent Co-authors

Shannon J. Turley(8), Ralph M. Steinman(6), Daniel S. Chen(5), Kayo Inaba(5), Jeanne Cheung(4), Jeong Kim(4), Lélia Delamarre(4), Wendy S. Garrett(4), Hartmut Koeppen(3), Mahesh Yadav(3), E. Sergio Trombetta(3), Michael Hull(3), Melanie Ebersold(3), Paul Webster(3), Sanjeev Mariathasan(2), Rafael Cubas(2), Suchit Jhunjhunwala(2), Romain Banchereau(2), Yagai Yang(2), Steve Lianoglou(2)